worldwid
strategi
aim
control
malari
parasit
mainli
plasmodium
falciparum
led
reduct
regard
diseas
incid
rate
mani
biologicallyderiv
antimalari
vaccin
candid
develop
date
involv
use
mani
experiment
anim
immens
amount
work
invest
million
dollar
review
provid
overview
current
state
main
result
clinic
trial
sporozoitetarget
vaccin
ie
parasit
stage
infect
liver
carri
research
group
area
variabl
malaria
transmiss
rate
howev
none
led
promis
result
regard
effect
control
diseas
therebi
make
necessari
complement
effort
findingintroduc
new
vaccin
candid
adopt
multiepitop
multistag
approach
base
minim
subunit
main
sporozoit
protein
involv
invas
liver
human
malaria
transmiss
diseas
high
morbimort
worldwid
caus
five
parasit
speci
genu
plasmodium
plasmodium
falciparum
plasmodium
vivax
plasmodium
oval
plasmodium
malaria
plasmodium
knowlesi
p
falciparum
highest
mortal
rate
follow
discoveri
parasit
lifecycl
begin
sporozoit
spz
form
transmit
human
bite
femal
anophel
mosquito
effort
elimin
diseas
becam
aim
elimin
vector
habitat
failur
strategi
world
health
organ
effort
aim
promot
control
programm
includ
longlast
insecticidetr
mosquito
net
indoor
spray
residu
insecticid
antimalari
drug
treatment
earli
rapid
diagnosi
govern
entiti
countri
malariaendem
area
invest
around
billion
us
dollar
annual
control
diseas
worldwid
despit
mani
effort
scientif
advanc
control
prevent
diseas
still
achiev
estim
million
case
malaria
malariarel
death
report
subsaharan
africa
especi
children
age
less
year
old
pregnant
women
also
estim
incid
rate
becom
reduc
statist
increasingli
highlight
need
global
attack
malaria
includ
develop
integr
multiepitop
multistag
longlast
vaccin
abl
induc
cellular
humor
immun
respons
ir
fundament
complementari
valuabl
tool
optim
exist
malaria
control
strategi
contribut
toward
elimin
diseas
would
therebi
help
save
hundr
thousand
live
everi
year
femal
anophel
mosquito
inject
minimum
spz
bite
remain
inocul
site
move
dermi
seek
capillari
enabl
migrat
toward
hepatocyt
high
heparan
sulphat
proteoglycan
hspg
content
membran
invad
last
min
make
spz
highli
suscept
host
ir
involv
small
amount
spz
infect
liver
cell
creat
bottleneck
parasit
reproduct
cycl
make
vaccin
target
spz
protein
parasit
hepat
stage
attract
vaccin
candid
stage
last
day
prolong
length
exposur
ir
detain
infect
therebi
hamper
parasit
develop
liver
symptom
appear
blood
stage
gametocyt
product
perpetu
parasit
lifecycl
fig
fundament
approach
complement
vaccin
p
falciparum
lifecycl
infect
femal
anophel
mosquito
inocul
spz
bite
host
travel
host
bloodstream
infect
hepatocyt
merozoit
releas
invad
erythrocyt
matur
variou
stage
ring
trophozoit
schizont
stage
undergo
asexu
multipl
lower
everi
h
releas
new
merozoit
perpetu
asexu
cycl
enter
sexual
cycl
becom
femal
male
gametocyt
ingest
mosquito
bite
infect
host
therebi
start
cycl
candid
target
asexu
erythrocyt
stage
million
merozoit
mrz
becom
expos
immun
system
extrem
short
period
time
around
min
therebi
reduc
chanc
success
approach
base
prolong
ir
exposur
time
effort
focus
develop
vaccin
target
spz
protein
recent
updat
report
vaccin
candid
clinic
phase
trial
includ
attenu
spz
vaccin
radiationattenu
spz
spz
administ
drug
coverag
geneticallyattenu
spz
vaccin
recombin
protein
vaccin
rt
recombin
viral
vector
vaccin
mva
metrap
csvac
metrap
mva
metrap
matrixm
adjuv
tabl
review
aim
analys
formul
dose
safeti
immunogen
current
clinic
trial
carri
regard
vaccin
candid
differ
studi
phase
includ
structur
protein
fragment
studi
main
thrust
research
group
develop
vaccin
p
falciparum
malaria
spz
stage
involv
spz
recombin
protein
dna
viral
vector
protein
fragment
attenu
spz
vaccin
induc
malaria
reactiv
tlymphocyt
count
high
antibodi
ab
titr
unfortun
advanc
candid
formul
date
limit
efficaci
howev
signific
develop
regard
phase
ii
iii
trial
tabl
prove
use
vaccin
develop
demonstr
ab
produc
immun
whole
attenu
spz
prevent
develop
hepat
infect
immobil
free
spz
avascular
dermi
prevent
erythrocyt
stage
develop
vaccin
base
approach
includ
radiationattenu
spz
ra
geneticallyattenu
parasit
gap
spz
administ
drug
coverag
mani
studi
aim
improv
attenu
spz
vaccin
focus
effort
produc
larg
repertoir
immunogen
evalu
impact
particular
regim
dosag
inocul
rout
therebi
enabl
effect
cellular
humor
immun
respons
achiev
p
falciparum
spz
pfspz
vaccin
main
candid
contain
live
radiationattenu
whole
asept
metabol
activ
spz
isol
salivari
gland
mosquito
infect
p
falciparum
pioneer
studi
evalu
effect
radiat
plasmodium
berghei
spz
abil
invad
develop
mous
liver
demonstr
infect
becam
reduc
higher
radiat
dose
mice
immun
xrayirradi
p
berghei
spz
becam
protect
homolog
challeng
challeng
plasmodium
vinckei
clinic
trial
attenu
spz
carri
human
volunt
base
forego
experiment
find
volunt
immun
bite
irradi
mosquito
infect
spz
p
falciparum
strain
clone
particip
protect
first
homolog
challeng
howev
volunt
protect
challeng
p
falciparum
strain
heterolog
challeng
result
show
attenu
spz
immun
could
repres
good
methodolog
develop
antimalari
vaccin
candid
though
involv
inconveni
impract
administr
rout
despit
demonstr
effect
concern
homolog
challeng
demonstr
immun
mosquito
bite
deposit
spz
dermi
subcutan
tissu
howev
yet
possibl
replic
innocul
use
standard
needl
led
mani
effort
equal
efficaci
classic
ra
vaccin
evalu
variabl
deliveri
method
inocul
rout
dose
administ
recogn
limit
one
studi
evalu
safeti
immunogen
differ
dose
pfspz
vaccin
via
subcutan
sc
vs
intraderm
id
rout
report
volunt
group
receiv
dose
pfspz
becam
protect
protect
volunt
one
immun
id
via
sc
tcell
respons
pfspz
antibodi
titr
openlabel
trial
perform
evalu
administr
rout
volunt
becam
protect
homolog
challeng
pf
strain
clone
control
human
malaria
infect
chmi
week
month
later
subject
parasitaemia
submit
repeat
heterolog
challeng
week
month
final
immun
p
falciparum
heterolog
strain
remain
without
parasitaemia
result
suggest
pfspz
vaccin
could
achiev
limit
last
protect
heterolog
strain
month
week
mva
metrap
phase
adult
group
metrap
increas
dose
vp
id
group
im
group
group
b
metrap
follow
week
mva
metrap
booster
dose
volunt
metrap
volunt
mva
metrap
ne
adult
yearsold
trial
metrap
vp
trial
b
vp
day
mva
metrap
intramuscular
rout
im
ne
children
infant
gambia
yearold
group
vp
metrap
pfu
mva
metrap
group
vp
metrap
pfu
mva
metrap
group
ml
hdcrv
group
vp
metrap
pfu
mva
metrap
group
vp
metrap
pfu
mva
metrap
group
ml
hdcrv
gambia
monthold
group
vp
metrap
pfu
mva
metrap
group
vp
metrap
pfu
mva
metrap
group
vaccin
gambia
weekold
group
vp
metrap
pfu
mva
metrap
group
vp
metrap
pfu
mva
metrap
group
vaccin
burkina
faso
monthold
vp
metrap
pfu
mva
metrap
ne
mva
metrap
phase
ii
adult
yearsold
n
metrap
vp
week
n
case
mva
metrap
pfu
n
control
antirabi
vaccin
ml
adjust
efficaci
pcr
posit
parasit
per
adult
yearsold
n
metrap
vp
week
n
case
mva
metrap
pfu
n
control
antirabi
vaccin
ml
pcr
posit
parasit
per
although
tcell
respons
increas
limit
second
third
immun
vaccin
welltoler
clinic
trial
efficaci
heterolog
strain
month
followup
without
incur
seriou
local
system
advers
event
ae
effect
week
month
last
immun
evalu
homolog
intraven
chmi
show
subject
receiv
dose
pfspz
becom
fulli
protect
promis
result
obtain
homolog
pfspz
chmi
prepar
strain
spz
howev
vaccin
effect
becam
consider
reduc
challeng
heterolog
strain
grade
ae
record
immun
dose
increas
pfspz
pfspz
adolesc
children
infant
age
month
old
older
assess
effect
pfspz
dose
immun
respons
children
infant
less
expos
p
falciparum
compar
adult
preexpos
longterm
p
falciparum
infect
signific
differ
found
age
group
regard
ae
amongst
vaccin
volunt
hand
found
vaccine
develop
antibodi
ab
pfcsp
evalu
humor
immun
respons
higher
respons
observ
children
age
year
old
receiv
pfspz
higher
ab
respons
children
infant
less
expos
p
falciparum
subject
live
nonendem
area
suggest
african
reduc
immun
respons
due
immunoregul
follow
longterm
exposur
p
falciparum
infect
effort
shown
pfspz
efficaci
adult
prior
exposur
p
falciparum
depend
administr
rout
induc
tissu
resid
cell
liver
dose
determin
degre
protect
durabl
homolog
heterolog
challeng
highlight
need
improv
dosag
strategi
altern
vaccin
approach
malariaendem
area
expect
phase
iii
trial
involv
around
peopl
age
yearsold
begin
earli
bioko
island
equatori
guinea
coast
trial
object
provid
data
regard
necessari
efficaci
safeti
regulatori
author
approv
trial
success
sanaria
intend
carri
anoth
clinic
trial
involv
peopl
island
hoffman
person
commun
approach
highlight
fact
antimalari
vaccin
base
immun
live
spz
chemoprophylact
cover
chloroquin
cpscq
achiev
protect
volunt
week
final
immun
protect
persist
year
furthermor
report
anoth
trial
includ
live
spz
evalu
chemoprophylact
cover
mefloquin
cpsmq
find
similar
safeti
efficaci
profil
cpscq
moreov
iv
administr
nonirradi
cryopreserv
spz
malariana
healthi
adult
volunt
take
chloroquin
part
prophylact
antimalari
treatment
vaccin
approach
denot
pfspzcvac
also
gave
efficaci
volunt
homolog
chmi
differ
immun
regimen
pharmacolog
altern
atovaquoneproguanil
azithromycin
pyrimethamin
current
studi
develop
safer
effect
methodolog
altern
anoth
approach
concern
genet
manipul
modifi
elimin
attenu
gene
parasit
alter
hepat
stage
infect
develop
genet
attenu
parasit
genedefici
spz
induc
protectioninduc
immun
p
berghei
mice
demonstr
lack
infect
blood
stage
first
clinic
trial
evalu
vaccin
safeti
immunogen
volunt
receiv
spz
gap
bite
infect
anophel
mosquito
show
vaccin
well
toler
mild
moder
local
system
reaction
volunt
develop
parasitaemia
day
exposur
phase
clinic
trial
involv
volunt
test
vaccin
lack
three
gene
express
p
falciparum
preerythrocyt
stage
administ
mosquito
bite
mild
moder
ae
report
absenc
parasitaemia
day
last
immun
demonstr
complet
attenu
preerythrocyt
develop
becom
arrest
humor
immun
respons
analysi
show
subject
develop
consider
igg
anticircumsporozoit
protein
csp
titr
therebi
support
claim
safe
immunogen
candid
efficaci
data
expect
anoth
candid
involv
genet
attenu
p
falciparum
spz
strain
elimin
gene
spz
liver
stage
asparaginerich
protein
slarp
gene
import
parasit
develop
liver
stage
plasmodium
falciparum
csp
locat
spz
surfac
crucial
parasit
morphogenesi
host
invas
variabl
length
kda
molecular
weight
ntermin
domain
contain
region
follow
tandem
repeat
region
consist
asparaginealanineasparagineprolin
nanp
amino
acid
aa
motif
repeat
time
interspac
four
time
asparaginevalineaspartateprolin
nvdp
asparagineprolineaspartateprolin
npdp
ctermin
domain
ctd
compris
region
ii
glycosylphosphatidylinositol
gpi
anchor
sequenc
fig
c
immunolog
respons
nanp
repeat
crucial
point
develop
cspbasad
vaccin
analysi
interact
human
monoclon
antibodi
mab
rt
vaccinederiv
nanp
repeat
led
identifi
minim
epitop
bind
confirm
increas
amount
ab
contact
improv
affin
repeat
sequenc
recent
studi
describ
mab
isol
p
falciparum
cspspecif
memori
bcell
volunt
immun
pfspz
vaccin
mab
crossreact
npdp
nvdp
nanp
repeat
region
ctd
fragment
therebi
enabl
bind
protein
alter
cleavag
process
limit
hepatocyt
invas
anim
model
next
step
involv
clinic
trial
run
path
malaria
vaccin
initi
determin
whether
mab
induc
protect
p
falciparum
infect
schemat
represent
metrap
vaccin
candid
lefthand
side
plasmid
use
express
metrap
vaccin
candid
either
mva
virus
involv
kanamycin
resist
kanr
blue
cytomegaloviru
intron
pcmv
inta
red
bovin
growth
hormon
termin
polya
bgh
polya
orang
escherichia
coli
bgalactosidas
gene
yellow
righthand
side
pftrap
tr
domain
ribbon
surfac
represent
pdb
recombin
vaccin
use
one
multipl
specif
antigen
induc
immunolog
respons
parasit
boost
coadminist
adjuv
therebi
overcom
problem
revers
virul
difficulti
obtain
suffici
amount
antigen
facilit
largescal
product
howev
use
unsuit
antigen
low
immunogen
high
genet
variat
rate
limit
emerg
effici
vaccin
diseas
malaria
one
main
antigen
involv
approach
p
falciparum
csp
use
subunit
rt
vaccin
rt
vaccin
studi
public
antimalari
vaccin
candid
clinic
phase
trial
accord
malaria
vaccin
guidelin
rt
consist
larg
segment
amino
acid
p
falciparum
strain
csp
protein
mani
variabl
epitop
identifi
tetrapeptid
csp
nanp
tandem
repeat
region
r
ctermin
region
contain
tcell
epitop
exclus
strain
becom
fuse
hepat
b
surfac
antigen
hbsag
express
saccharomyc
cerevisia
yeast
cell
fig
selfassembl
viruslik
particl
vlp
maximum
rt
sequenc
insert
vlp
adjuv
system
welltoler
rt
induc
highest
anticsp
tcell
respons
compar
rt
three
dose
administ
children
infant
instead
two
dose
ab
persist
least
three
half
year
follow
immun
anticsp
antibodi
concentr
singl
rt
booster
dose
month
initi
immun
persist
year
even
though
titr
becam
reduc
level
preced
booster
dose
cellular
humor
immunolog
respons
associ
protectioninduc
respons
asymptomat
symptomat
parasitaemia
state
howev
consider
variat
result
inexplic
exampl
children
might
suffer
malaria
spite
high
anticsp
titr
clinic
trial
estim
vaccin
efficaci
follow
last
immun
use
standard
three
dose
scheme
howev
becam
reduc
last
week
followup
clinic
evalu
result
suggest
rt
consid
safe
spite
induc
slight
moder
local
reactogen
tend
escal
increas
dose
regardless
age
dose
highli
immunogen
induc
anticsp
antihbsag
ab
greater
children
age
yearsold
furthermor
demonstr
inductor
effect
rt
protect
associ
particular
human
leukocyt
antigen
hla
allel
safeti
immunogen
data
provid
basi
expand
evalu
new
dose
strategi
vaccin
schedul
extend
followup
period
use
larger
sampl
paediatr
popul
resid
malariaendem
region
clinic
trial
differ
age
paediatr
popul
estim
efficaci
least
month
followup
year
attribut
intens
transmiss
choic
adjuv
age
popul
immun
howev
significantli
higher
ab
respons
report
third
dose
even
though
longlast
target
popul
immun
rt
infant
safeti
efficaci
profil
investig
due
administ
vaccin
includ
expand
programm
immun
epi
found
rt
interfer
immunolog
respons
epi
antigen
coadminist
infant
efficaci
first
singl
episod
malaria
efficaci
episod
period
rt
favour
safeti
profil
suggest
vaccin
could
administ
use
month
scheme
scheme
chosen
clinic
evalu
multicentr
phase
iii
trial
deliv
vaccin
via
epi
demonstr
scheme
involv
complet
dose
rt
month
togeth
third
fraction
dose
month
increas
protect
chmi
improv
immunogen
increas
specif
antibodi
avid
somat
hypermut
frequenc
bcell
effect
chang
vaccin
scheme
dose
protectioninduc
immun
vaccin
efficaci
must
thu
studi
depth
doubl
blind
random
control
trial
carri
evalu
rt
efficaci
involv
particip
divid
two
age
group
weekold
monthold
subsaharan
africa
countri
differ
malaria
transmiss
rate
month
first
vaccin
find
efficaci
sever
malaria
combin
age
categori
clinic
malaria
monthold
group
year
followup
efficaci
episod
clinic
malaria
greater
monthold
group
compar
weekold
group
sever
malaria
respect
found
followup
group
infant
age
month
old
receiv
rt
efficaci
vaccin
episod
malaria
becam
reduc
fifth
year
averag
efficaci
followup
period
protect
becam
reduc
time
elaps
becom
undetect
exhibit
neg
efficaci
last
studi
period
group
receiv
three
dose
led
includ
booster
dose
vaccin
scheme
infant
becam
month
old
consid
efficaci
lower
infant
rt
safeti
profil
confirm
accord
data
phase
iiii
trial
local
system
grade
ae
incid
low
studi
group
similar
frequenc
fourth
dose
rt
reactogen
system
local
ae
day
follow
vaccin
compar
group
receiv
three
dose
sever
malaria
incid
becam
reduc
follow
vaccin
rt
children
tanzania
kenya
burkina
faso
followup
regardless
immun
scheme
european
medicin
agenc
ema
evalu
rt
clinic
develop
issu
cautiou
scientif
opinion
regard
qualiti
even
though
preclin
studi
result
publish
year
clinic
evalu
began
recent
public
trial
recommend
carri
pilot
introduct
particip
three
subsaharan
countri
kenya
malawi
ghana
moder
high
level
malari
transmiss
administ
fourdos
scheme
monthold
age
group
also
suggest
initi
scheme
minimum
interv
dose
follow
dose
month
dose
sever
point
regard
rt
rais
concern
high
parasitaemia
level
individu
consid
protect
parasitaemia
select
csp
region
high
genet
variabl
fullydefin
adjuv
system
use
mainli
consist
saponin
induc
cell
activ
poorli
understood
mechan
rt
compon
induc
proapoptot
signal
shortterm
efficaci
subunitbas
vaccin
base
singl
fusion
protein
consist
p
falciparum
strain
csp
cterminu
bound
hbsag
nterminu
develop
improv
version
rt
contain
larger
amount
csp
compar
hbsag
promot
potent
humor
immun
respons
csp
minimum
ab
hbsag
portion
efficaci
exposur
transgen
spz
improv
balbc
mice
given
low
dose
clinic
trial
carri
evalu
safeti
immunogen
administ
adjuv
healthi
english
particip
receiv
three
dose
vaccin
day
trial
good
anticsp
ab
respons
observ
followup
use
dose
compar
rt
level
induc
malaria
dose
welltoler
howev
safetyrel
ae
studi
regist
clinicaltrialsgov
although
inform
publish
viral
vector
repres
promis
tool
vaccin
develop
enabl
intracellular
antigen
express
increas
abil
gener
robust
cytotox
tlymphocyt
respons
proinflammatori
interferon
cytokin
product
without
need
adjuv
howev
great
concern
regard
genotox
due
possibl
viral
genom
integr
led
mani
effort
aim
find
high
level
safeti
efficaci
sever
viral
bacteri
parasit
vector
use
antimalari
vaccin
candid
current
mani
clinic
trial
explor
advantag
increas
potenti
acceler
use
vaccin
antimalari
vaccin
develop
use
chimpanze
adenoviru
modifi
vaccinia
viru
ankara
mva
insert
gene
encod
thrombospondinrel
adhes
protein
trap
multipl
epitop
chain
metrap
hybrid
thu
base
pair
bp
insert
encod
singl
aalong
peptid
cover
complet
p
falciparum
trap
sequenc
fuse
chain
malaria
tand
bcell
epitop
target
mhc
class
mhc
class
ii
murin
fig
mva
viru
highli
attenu
use
effici
nonrepl
viral
vector
develop
new
vaccin
serotyp
circul
human
popul
thu
neutral
antibodi
target
seldom
demonstr
trap
belong
famili
protein
found
micronem
invas
stage
parasit
phylum
apicomplexa
apic
complex
secretor
vesicl
kda
aalong
conserv
type
micronem
protein
two
bind
region
von
willebrand
type
vwa
region
includ
metaliondependentadhesionsit
mida
tsr
domain
region
ii
known
role
proteinprotein
interact
also
prolinerich
region
region
iii
transmembran
domain
region
iv
acid
ctermin
cytoplasm
tail
fig
sequenti
administr
mva
vector
space
interv
time
primari
heterolog
booster
dose
aim
induc
tcell
produc
interferon
gamma
due
main
role
mediat
protect
hepat
stage
studi
particip
report
local
ae
day
initi
vaccin
pain
erythema
oedema
pruritu
heat
particip
receiv
id
rout
vaccin
report
local
ae
lower
incid
report
receiv
metrap
intramuscular
im
rout
therebi
conclud
id
rout
associ
greater
local
reactogen
compar
im
rout
system
ae
report
phase
studi
includ
fatigu
gener
discomfort
fever
occur
resolv
first
h
vaccin
increas
vaccin
dose
regardless
administr
rout
data
contrari
describ
anoth
studi
greater
reactogen
associ
vaccin
rout
occur
im
compar
id
ie
signific
differ
dose
studi
conclud
mva
metrap
reactogen
greater
ae
incid
howev
welltoler
regard
alter
reflect
laboratori
test
increas
transaminas
level
follow
vaccin
metrap
expens
alanin
aminotransferas
alt
eosinophilia
thrombocytopenia
becam
resolv
particip
contrari
describ
studi
involv
westafrican
children
alter
particip
haematolog
biochem
test
report
follow
vaccin
trial
involv
adult
seneg
assess
vaccin
efficaci
use
polymeras
chain
reaction
pcr
assay
abl
detect
blood
pcr
posit
particip
vaccin
metrap
booster
dose
mva
metrap
control
patient
receiv
antirabi
vaccin
posit
pcr
give
efficaci
statist
signific
thu
group
result
efficaci
obtain
studi
kenya
use
cox
regress
show
overal
vaccin
efficaci
popul
csvac
vaccin
mva
encod
p
falciparum
cs
protein
continu
line
research
plasmid
dna
antimalari
vaccin
cs
insert
codonoptim
cdna
encod
cs
protein
truncat
ctermin
extrem
therebi
lack
ctermin
aa
thu
omit
gpi
anchor
fig
seriou
ae
found
evalu
vaccin
safeti
profil
slight
resolv
within
h
found
volunt
suffer
one
local
ae
follow
vaccin
cs
compar
volunt
suffer
one
system
ae
follow
vaccin
mostli
affect
particip
receiv
vp
dose
conclud
mva
cs
reactogen
volunt
antigenspecif
tcell
respons
two
dose
cs
compar
group
vp
group
ii
vp
evalu
immunogen
reduc
level
report
day
statist
signific
respons
volunt
increas
significantli
day
administr
mva
cs
follow
gradual
decreas
followup
day
tcell
polyfunction
also
evalu
conclud
produc
greater
tnf
level
unlik
valu
produc
similar
amount
signific
differ
volunt
igg
titr
detect
limit
day
zero
mva
cs
booster
dose
produc
signific
increas
ab
concentr
day
group
compar
group
without
booster
dose
likewis
averag
ab
respons
greater
group
compar
group
day
statist
signific
differ
tabl
give
detail
inform
group
chmi
studi
p
falciparum
spz
involv
challeng
consist
infecti
bite
mosquito
evalu
vaccin
efficaci
combin
cs
metrap
report
infect
control
vaccin
particip
diagnos
malaria
experienc
least
one
sever
ae
challeng
conclud
metrap
greater
clinic
efficaci
induc
steril
protect
particip
unlik
cs
induc
steril
protect
vaccin
particip
vaccin
candid
metrap
mva
metrap
safeti
immunogen
evalu
administ
matrixm
saponinbas
adjuv
stimul
immun
respons
antigen
present
local
lymph
node
increas
local
reactogen
reveal
phase
studi
involv
particip
vaccin
adjuv
pain
inocul
area
commonli
occur
local
ae
system
ae
report
group
receiv
vaccin
adjuv
fever
greater
preval
volunt
control
group
matrixm
group
matrixm
group
regard
cellular
humor
immunogen
differ
control
group
group
receiv
vaccin
adjuv
consid
object
use
adjuv
boost
antigeninduc
ir
author
conclud
use
matrixm
adjuv
lead
signific
chang
vaccin
immunogen
recent
scientif
advanc
given
rise
need
safer
formul
increas
antigen
efficaci
nanovaccinolog
emerg
last
year
sure
come
play
import
role
malaria
vaccin
develop
use
nanoparticl
enabl
antigen
stabil
immunogen
select
administr
slow
releas
becom
improv
characterist
facilit
develop
differ
vaccin
nanoparticl
approv
human
use
vari
composit
form
surfac
properti
size
nm
similar
cell
compon
enabl
enter
cell
via
mechan
pinocytosi
nanoparticl
use
deliveri
system
vaccin
candid
aim
prevent
diseas
caus
viral
bacteri
parasit
fungal
pathogen
well
noninfecti
diseas
like
cancer
alzheim
hypertens
nicotin
addict
regard
parasit
diseas
csp
protein
p
falciparum
encapsul
therebi
enabl
better
ab
respons
inhibit
invas
hepatocyt
induc
immunolog
respons
could
contribut
toward
develop
longlast
protectioninduc
immun
promis
altern
deliveri
system
subunitbas
vaccin
develop
recent
use
vaccin
candid
sever
infecti
diseas
hiv
toxoplasma
sar
influenza
andor
malaria
techniqu
known
selfassembl
protein
nanoparticl
sapn
involv
express
peptid
protein
contain
target
antigen
coval
link
adjuv
sequenc
flagellinderiv
case
univers
epitop
pandr
thelper
epitop
padr
sequenc
peptideprotein
selfassembl
specif
condit
thu
form
nm
nanoparticl
formul
emulsifi
adjuv
glase
armi
liposom
formul
alf
manag
produc
protectioninduc
respons
sever
diseas
howev
studi
requir
expedit
understand
chang
nanoparticl
properti
might
affect
immunolog
respons
malaria
thu
contribut
toward
effect
vaccin
design
hand
advanc
made
field
bioinformat
genet
engin
molecular
biolog
contribut
toward
use
altern
methodolog
approach
one
approach
revers
vaccinolog
rel
rapid
identif
vaccin
candid
molecul
base
silico
analysi
complet
sequenc
genom
variou
pathogen
studi
evalu
microbi
biolog
hostpathogen
interact
methodolog
use
cultur
noncultur
microorgan
togeth
comput
analysi
enabl
dna
sequenc
encod
protein
play
import
role
parasit
biolog
identifi
therefor
becom
possibl
vaccin
candid
great
scientif
progress
made
regard
research
antimalari
vaccin
candid
last
four
decad
result
strategi
promot
scientif
academ
govern
institut
worldwid
extens
gener
support
offici
entiti
philanthrop
organ
clearli
deepli
commit
resolv
malaria
conundrum
current
antimalari
vaccin
candid
limit
efficaci
due
intrins
complex
problem
multipl
factor
govern
appropri
immun
respons
amount
extern
factor
choic
antigen
use
quit
complic
due
factor
parasit
complex
lifecycl
involv
two
reproduct
cycl
sexual
asexu
differ
develop
stage
two
host
anophel
mosquito
human
be
ad
multipl
invas
rout
describ
far
target
cell
hepatocyt
andor
erythrocyt
parasit
abil
modifi
gene
express
genet
variabl
p
falciparum
circul
strain
likewis
result
date
led
conclus
whole
organismor
subunitbas
vaccin
involv
singl
parasit
variant
insuffici
cover
wide
genet
divers
develop
antimalari
vaccin
base
subunit
deriv
protein
involv
parasit
invas
infect
multiepitop
cover
parasit
differ
form
multistag
overcom
complic
suggest
sever
decad
subunit
must
consist
sequenc
conserv
amongst
p
falciparum
circul
strain
induc
straintranscend
vaccin
overcom
parasit
genet
variabl
next
major
challeng
concern
host
genet
variabl
particularli
major
histocompat
class
ii
mhcii
complex
molecul
exert
mechan
synthes
protein
encod
hladr
region
hladr
region
encod
genet
variant
group
allel
famili
call
etc
parasit
protein
interact
human
immun
system
analys
predict
b
epitop
use
netmhciipan
predictor
andor
vivo
evalu
model
aotu
monkey
highli
suscept
develop
human
malaria
ident
immun
system
human
variou
adjuv
deliveri
system
develop
improv
vaccin
efficaci
clinic
trial
spzstage
antimalari
vaccin
involv
use
adjuv
consist
combin
immunostimul
viral
vector
adjuv
use
rtss
consist
combin
immunostimul
monophosphoryl
lipid
mpl
liposom
formul
quillaja
saponaria
fraction
waterinoil
emuls
chimpanze
adenoviru
chad
develop
vector
due
concern
human
adenovirus
preexist
immun
immunolog
potenc
vaccin
involv
viral
vector
deriv
serotyp
chad
modifi
vaccinia
viru
ankara
mva
wide
evalu
human
seen
safe
potent
tcell
ab
induc
review
thu
describ
great
amount
knowledg
accumul
date
whilst
await
clinic
phase
result
candid
describ
togeth
research
altern
still
develop
well
difficulti
challeng
still
overcom
part
long
fruit
way
develop
vaccin
target
diseas
malaria
high
global
impact
ideal
approach
demonstr
favour
result
could
use
regard
mani
infecti
diseas
afflict
human
